Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RPS6KA2 | Q15349 | 3/20 | 0.40 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21996116 | 0.87 | GRM5 (0.42) | TSHRRXFP1MEN1KMT2ARPS6KA2 | |
| SCHEMBL21996143 | 0.82 | HDAC1 (0.52) | LMNATSHRMEN1KMT2APOLB | |
| SCHEMBL21996147 | 0.82 | MAPK1 (0.41) | LMNATSHRL3MBTL1RXFP1MEN1 | |
| SCHEMBL582153 | 0.77 | RET (0.44) | TSHRALDH1A1POLB | |
| SCHEMBL21996154 | 0.74 | RXFP1 (0.40) | LMNATSHRL3MBTL1RXFP1MEN1 | |
| SCHEMBL11815790 | 0.74 | LMNA (0.44) | LMNATSHRL3MBTL1RXFP1MEN1 | |
| SCHEMBL20046088 | 0.72 | CA2 (0.39) | LMNAMEN1KMT2AALDH1A1POLB | |
| SCHEMBL6489508 | 0.71 | LMNA (0.54) | LMNATSHRL3MBTL1RXFP1MEN1 | |
| SCHEMBL26625800 | 0.71 | ACHE (0.61) | RPS6KA2GRM5ACHEHSD17B10 | |
| SCHEMBL18669187 | 0.71 | ACHE (0.61) | RPS6KA2GRM5ACHEHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11292782-B2 | Diarylhydantoin compounds and methods of use thereof | NUVATION BIO INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-11292782-B2 | Diarylhydantoin compounds and methods of use thereof | NUVATION BIO INC. (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3886853-A1 | DIARYLHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | Nuvation Bio Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-20200199098-A1 | DIARYLHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-06-25 | — | — | US | disclosed |
| US-20200199098-A1 | DIARYLHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-06-25 | — | — | US | disclosed |
| WO-2020113088-A1 | DIARYLHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | NUVATION BIO INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199098-A1 | DIARYLHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | SHBG, NCOA3, NCOA1 | LMNA 1647/4885TSHR 1702/4885L3MBTL1 3935/4885 |
| US-11292782-B2 | Diarylhydantoin compounds and methods of use thereof | SHBG, NCOA3, NCOA1 | LMNA 1647/4885TSHR 1702/4885L3MBTL1 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.